NRC AN 019

Drug Profile

NRC AN 019

Alternative Names: AN-019; NRC-AN-019; NRC/AN/019

Latest Information Update: 12 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Natco Pharma
  • Class Antineoplastics; Pyrimidines
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 11 Feb 2016 No development reported - Phase-II for Chronic myeloid leukaemia (Second-line therapy or greater) in India (PO)
  • 11 Feb 2016 No development reported - Phase-II for Solid tumours (Second-line therapy or greater) in India (PO)
  • 04 Jun 2013 Final efficacy, adverse events and pharmacokinetics data from a phase I trial in Chronic myeloid leukaemia presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top